Literature DB >> 11332158

Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy.

M Penz, G V Kornek, M Raderer, H Ulrich-Pur, W Fiebiger, W Scheithauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11332158     DOI： 10.1023/a:1011184609963

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  15 in total

Review 1.  Neurologic toxicities of cancer therapies.

Authors:  Robert Cavaliere; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

2.  Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study.

Authors:  Stefan von Delius; Florian Eckel; Stefan Wagenpfeil; Martina Mayr; Konrad Stock; Frank Kullmann; Florian Obermeier; Johannes Erdmann; Renate Schmelz; Stefan Quasthoff; Helmuth Adelsberger; Rainer Bredenkamp; Roland M Schmid; Christian Lersch
Journal:  Invest New Drugs       Date:  2006-09-13       Impact factor: 3.850

Review 3.  Interventions for preventing neuropathy caused by cisplatin and related compounds.

Authors:  James W Albers; Vinay Chaudhry; Guido Cavaletti; Ross C Donehower
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

Review 4.  [Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options].

Authors:  T Kowalski; C Maier; A Reinacher-Schick; U Schlegel
Journal:  Schmerz       Date:  2008-02       Impact factor: 1.107

5.  Oral Calcium Ameliorating Oxaliplatin-Induced Peripheral Neuropathy.

Authors:  Muhammad Wasif Saif
Journal:  J Appl Res       Date:  2004-01-01

6.  Neuroprotective effect of neurotropin on chronic oxaliplatin-induced neurotoxicity in stage II and stage III colorectal cancer patients: results from a prospective, randomised, single-centre, pilot clinical trial.

Authors:  R X Zhang; Z H Lu; D S Wan; X J Wu; P R Ding; L H Kong; Z Z Pan; G Chen
Journal:  Int J Colorectal Dis       Date:  2012-06-05       Impact factor: 2.796

7.  Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.

Authors:  Gregory D Leonard; Maurice A Wright; Mary G Quinn; Suzanne Fioravanti; Nancy Harold; Barbara Schuler; Rebecca R Thomas; Jean L Grem
Journal:  BMC Cancer       Date:  2005-09-16       Impact factor: 4.430

8.  Management of oxaliplatin-induced peripheral neuropathy.

Authors:  M Wasif Saif; John Reardon
Journal:  Ther Clin Risk Manag       Date:  2005-12       Impact factor: 2.423

9.  Effects of calcium and magnesium on acute and chronic neurotoxicity caused by oxaliplatin: A meta-analysis.

Authors:  Rui Ao; Yu-Hui Wang; Rui-Wen Li; Zheng-Rong Wang
Journal:  Exp Ther Med       Date:  2012-08-22       Impact factor: 2.447

10.  Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.

Authors:  Yanyun Zhu; Junlan Yang; Shunchang Jiao; Tiefeng Ji
Journal:  World J Surg Oncol       Date:  2013-01-25       Impact factor: 2.754
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.